Distributed Bio Collaborates With Washington University School of Medicine
Distributed Bio, a global leader in computational optimization of fully human monoclonal antibody libraries, is pleased to announce a multi target research collaboration with John DiPersio, MD, PhD, Chief of the Division of Oncology at Washington University School of Medicine and Deputy Director of the Alvin J. Siteman Cancer Center in St. Louis. Distributed Bio will use its proprietary SuperHuman antibody discovery and engineering platform to discover and optimize therapeutics in collaboration with Dr. DiPersio.
“We are delighted to collaborate with Dr. DiPersio on antibody discovery,” says Jacob Glanville, Co-Founder and Chief Executive Officer of Distributed Bio. “The SuperHuman Platform represents the culmination of a decade of our research in computational library design. From analyzing thousands of human immune systems with our machine learning AbGenesis platform, we have harvested from nature the rules of making exceptional therapeutic repertoires. The result is a library of 76 billion antibodies that contains over 5,000 hits against any antigen, thermostable, non-immunogenic, pre-screened by human blood and therapeutically developed in advance to avoid engineering delays downstream. This is an order of magnitude more molecules than can be generated by other technologies, and enables our partners to search for ultra-specific, species-cross reactive therapeutic antibodies at unprecedented speeds. The libraries overcome many of the limitations of other monoclonal generation technologies that have resulted in a unique engineering opportunity: a library that can generate unique and developable hits against every antigen tested, enabling routine success against targets that used to be nearly insurmountable – GPCRs, Ion Channels, pMHC complexes, broadly-neutralizing antibodies against HIV, therapeutic anti-idiotypic antibodies, bi-epitopic antibodies, and mouse/NHP/human cross-reactive antibodies.”
Under the terms of the collaboration, Distributed Bio will use its SuperHuman antibody library to discover novel therapeutic antibodies to targets selected by Dr. DiPersio and will also use its Tumbler technology to optimize clones that he already has identified. The lead clones will then be further developed by Dr. DiPersio.
About Distributed Bio
Distributed Bio is a computational immunoengineering biotechnology group, self-funded by the success of the stack of antibody discovery, optimization and analysis technologies to partners across the pharmaceutical industry. Our mission is to disrupt biologic engineering with big data, machine learning, and computational immunology-driven design.
From a team that includes inventors of antibody repertoire sequencing technologies, their AbGenesis antibody and TCR repertoire analysis and engineering platform enables partners to analyze antibody repertoires by high-throughput sequence, Sanger sequence, and functional assay without requiring large data center investments or local bioinformatics specialists. By using AbGenesis to analyze thousands of antibody repertoires and antibody libraries, they developed the computationally optimized SuperHuman 2.0 antibody library, the SLiC single light chain library, the Tungsten humanized VHH library, CAR-T discovery library, and the Cosmic antibody library.
In 2018, Distributed Bio entered into an exclusive partnership with Charles River, a leading provider of essential products and services for pharmaceutical and biotechnology companies, government agencies and leading academic institutions.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200114005196/en/
Contact information
Giles Day, COO, Distributed Bio Inc
info@distributedbio.com +1-415-489-0246
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Cessna Citation Ascend Achieves FAA Certification, Bringing Advanced Features to the Most Popular Midsize Business Jet Family6.11.2025 15:15:00 EET | Press release
The Cessna Citation Ascend, designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company, achieved a major milestone Wednesday, November 5, as the Federal Aviation Administration (FAA) awarded type certification for the aircraft, with entry into service expected later this year. The aircraft boasts an entirely new cockpit, improved performance and luxurious flat floor cabin, giving customers versatility and flexibility to accomplish their mission. Two flight test articles completed more than 1,000 flight hours and numerous certification tests to achieve FAA certification. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251106032431/en/ Cessna Citation Ascend achieves FAA certification, bringing advanced features to the most popular midsize business jet family (Photo credit: Textron Aviation). “The Citation Ascend’s successful flight test program reflects our teams’ expertise in obtaining FAA certifica
FIM Partners and Loomis Sayles Announce Transition of Global Emerging Market Equities Team6.11.2025 15:00:00 EET | Press release
FIM Partners today announced it has entered into an agreement with Loomis, Sayles & Company, to acquire the Global Emerging Market Equities (GEM) investment team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251106799715/en/ Overview of the GEM Team and FIM Led by Ashish Chugh, Portfolio Manager and Head of Global Emerging Market Equities, the GEM Team follows a high conviction investment philosophy anchored in deep, fundamental research and a private equity-style approach to diligence and ownership. The team invests in high quality companies and those transitioning toward higher quality, leveraging its proprietary insights to identify long-term value creation opportunities across emerging markets. With an active, bottom-up, benchmark-agnostic strategy, the team builds high-conviction, concentrated, quality-focused portfolios that reflect a true ownership mindset. Founded in 2008, FIM Partners is a leading asset manager fo
Debiopharm Takes a Step Forward for Children With CPP: Enrollment Completion for the Phase III Trial Evaluating the First Ever Yearly Injectable Triptorelin Formulation6.11.2025 15:00:00 EET | Press release
Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to develop innovative therapies and to improve patient quality of life, today announced the successful completion of patient enrollment in its open-label, single-arm, multi-center Phase III study (NCT06129539) ‘A Study to Assess the Efficacy, Safety and Pharmacokinetics of Debio 4326 in Pediatric Participants Receiving Gonadotropin-Releasing Hormone Agonist Therapy for Central Precocious Puberty (LIBELULATM)’. The completion of enrollment is a significant milestone for the development of Debio 4326, a unique injectable, biodegradable 12-month extended-release formulation of the established treatment, triptorelin. The LIBELULATM trial is being conducted across the United States, Argentina, Brazil, Chile, and Mexico, leveraging Debiopharm's proprietary DEBIO SPHERETMLong-Acting Release Platform technology and expertise in developing extended-release formulations to potentially reduce the freq
IFCO’s circular model delivers global impact: Five years of progress marked with 2025 ESG report6.11.2025 15:00:00 EET | Press release
IFCO, a global leader in reusable packaging containers (RPCs) for fresh food, today published its ESG Report 2025, marking the successful completion of its five-year sustainability strategy, Thriving in the Circular Economy. Over the last five years, IFCO has advanced every one of its 18 ESG goals, delivering measurable progress for the planet, people, partners, and customers while laying the groundwork for the next iteration of its sustainability objectives. The ESG Report 2025 confirms IFCO’s position as a global leader in circular packaging and highlights the role of reuse in addressing some of the sector’s most pressing challenges. Since IFCO’s founding in 1992, it has dedicated itself to eliminating packaging and food waste in the fresh grocery supply chain, enhancing efficiencies across the value chain and sharing the resulting long-term value with stakeholders. With operations in more than 50 countries and partnerships with 18,000 growers and 300 retailers, IFCO’s scale enables
U.K. Continues to Lead Europe in Shareholder Activism with 44% Year-on-Year Surge, According to Diligent Market Intelligence6.11.2025 14:00:00 EET | Press release
The U.K. remains Europe’s most active market for shareholder activism, with a 44% year-on-year increase in targeted companies, according to the Corporate Governance in Europe 2025report by Diligent Market Intelligence (DMI). Between September 2024 and August 2025, 52 U.K. companies faced activism, compared to 36 over the same timeframe in 2024, underscoring the market’s heightened shareholder engagement. “The U.K. remains the primary driver of public-facing engagement in Europe, with other European markets increasingly witnessing similar strategies when behind-the-scenes efforts fail,” said Josh Black, Editor-in-Chief, Diligent Market Intelligence. “Activism in Europe runs the full gamut from hostile media campaigns to more private engagements but there is no doubt that boards should prepare for anything in what looks likely to be a very busy annual meeting season.” Produced in association with White & Case, a global law firm, thereport reveals that while smaller-cap companies accounte
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom